Enzymatically inactive granzyme a and uses therefore
AssigneeSaint Louis University
InventorsDaniel F. HOFT, Valerio RASI
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to recombinant mutant Granzyme A molecules that lack enzymatic activity and their use in inhibiting Mycobacterium tuberculosis and treating the related disease states.
Claims20
A method of treating or preventing infection of a human subject with Mycobacterium tuberculosis comprising providing to said subject an effective amount of a recombinant, homodimeric, enzymatically inactive mutant Granzyme A having a serine-*alanine substitution corresponding to position 212 of SEQ ID NO:
- 1.
A recombinant, enzymatically inactive mutant Granzyme A having a serine-*alanine substitution corresponding to position 212 of SEQ ID NO:
- 1, or a nucleic acid (e.g., RNA or DAN), or an expression construct (e.g., viral or non-viral) encoding the same.
The mutant Granzyme A, nucleic acid or expression construct of claim 17, wherein said mutant Granzyme A, nucleic acid or expression construct is frozen.
Dependencies are inferred from the claim text.